TY - JOUR
T1 - Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer
AU - Buzdar, Aman U.
AU - Gutterman, Jordan U.
AU - Blumenschein, George R.
AU - Hortobagyi, Gabriel N.
AU - Tashima, Charles K.
AU - Smith, Terry L.
AU - Hersh, Evan M.
AU - Freireich, Emil J.
AU - Gehan, Edmund A.
PY - 1978/3
Y1 - 1978/3
N2 - For the past 34 months, a combination of 5‐fluorouracil, adriamycin, cyclophosphamide, and BCG (FAC‐BCG) was evaluated as adjuvant treatment in stage II and III breast cancer patients with positive axillary nodes. In the group of 131 patients receiving FAC‐BCG, the estimated proportion remaining disease‐free at 2 years from surgery was 91% compared to an estimated 69% in a group of 151 historical control patients (p < 0.01). This advantage was statistically significant in all subgroups except for patients with primary tumor less than 3 cm and for patients with less than 4 positive nodes. Estimated 2‐year survival rates were 96% for FAC‐BCG patients and 86% for control (p = 0.02). Treatment was well tolerated. Adjuvant FAC‐BCG seems effective in prolonging disease‐free interval and early survival in patients with stage II and III breast cancer. Its long term efficacy will require longer follow‐ups.
AB - For the past 34 months, a combination of 5‐fluorouracil, adriamycin, cyclophosphamide, and BCG (FAC‐BCG) was evaluated as adjuvant treatment in stage II and III breast cancer patients with positive axillary nodes. In the group of 131 patients receiving FAC‐BCG, the estimated proportion remaining disease‐free at 2 years from surgery was 91% compared to an estimated 69% in a group of 151 historical control patients (p < 0.01). This advantage was statistically significant in all subgroups except for patients with primary tumor less than 3 cm and for patients with less than 4 positive nodes. Estimated 2‐year survival rates were 96% for FAC‐BCG patients and 86% for control (p = 0.02). Treatment was well tolerated. Adjuvant FAC‐BCG seems effective in prolonging disease‐free interval and early survival in patients with stage II and III breast cancer. Its long term efficacy will require longer follow‐ups.
UR - http://www.scopus.com/inward/record.url?scp=0018178240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018178240&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(197803)41:3<1064::AID-CNCR2820410340>3.0.CO;2-Q
DO - 10.1002/1097-0142(197803)41:3<1064::AID-CNCR2820410340>3.0.CO;2-Q
M3 - Article
C2 - 638948
AN - SCOPUS:0018178240
SN - 0008-543X
VL - 41
SP - 1064
EP - 1075
JO - Cancer
JF - Cancer
IS - 3
ER -